HIF1A and chronic myelogenous leukemia, BCR-ABL1 positive: This study initiated to clarify the expression of HIF-1α and downstream target genes in CML cells, elucidate the combined effect of the HIF-1α inhibitor 2-ME2 and the second-generation TKI dasatinib on CML cells, and further demonstrate the possible action mechanism of the combined therapy of both agents.